SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2024 Annual Meeting of Stockholders on Wednesday, May 29, 2024, at 9:00 a.m. PT. The Annual Meeting will be held in virtual format only via live audio webcast. Vir Biotechnology's stockholders of record at the close of business on April 1, 2024, the record date for the Annual M...
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting new data from the Company's chronic hepatitis delta and chronic hepatitis B programs have been accepted for presentation at the annual meeting of the European Association for the Study of the Liver, EASL™ Congress 2024, taking place in Milan, Italy from June 5-8. This includes...
BEAVERTON, Ore.--(BUSINESS WIRE)-- #familyfestivals--Reser's Fine Foods kicks off 2024 ‘Good Times Tour' with free delicious samples and fun activities in their booth at festivals throughout 2024.
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the EASL Congress has changed the Company's Phase 2 SOLSTICE hepatitis delta presentation from a late-breaker poster to an oral presentation. The SOLSTICE data will be presented on June 8 during the annual meeting of the European Association for the Study of the Liver, EASL™ Congress 2024, taking place in Mila...
DURHAM, N.C. and BEIJING, May 13, 2024 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet need, today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) granted Breakthrough Therapy Des...
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2024. “We are excited to share important data from our Phase 2 chronic hepatitis delta SOLSTICE trial at the upcoming EASL congress. This milestone brings us closer to addressing the significant unmet medical need for the mi...
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is scheduled to participate in a fireside chat at the BofA Securities Healthcare Conference 2024 on Tuesday, May 14, at 4:20 p.m. PT / 7:20 p.m. ET. A live webcast of the fireside chat will be made available under Events & Presentations in the...
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.